PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?

Adashek, Jacob J; Aguiar, Pedro N; Castelo-Branco, Pedro; Lopes, Gilberto L; De Mello, Ramon Andrade

http://hdl.handle.net/10400.1/12884

Use this identifier to reference this record.

Name:	Description:	Size:	Format:
fon-2019-0044.pdf		1.23 MB	Adobe PDF	Download

Send Feedback

Authors

Adashek, Jacob J

Aguiar, Pedro N

Castelo-Branco, Pedro

Lopes, Gilberto L

De Mello, Ramon Andrade

Abstract(s)

Breast cancer is a very important disease in terms of public health worldwide. Several patients are diagnosed and follow to a progressive disease every year. CDK4/6 inhibitors (CDKi) were a paradigm shift in the treatment of hormone receptor-positive (HR+), HER2-negative advanced breast cancer (aBC).

Keywords

Antineoplastic combined chemotherapy Protocols Breast neoplasms Clinical trials, Phase II as topic Clinical Trials, Phase III as topic Female Humans Treatment outcome